However, despite some delay in tumor progression seen upon transfer of NKp30-CD137 CAR TCRKO T cells, we could not observe better persistence of NKp30-CD137 CAR TCRKO engineered T cells compared to CD28-costimulated CAR T lymphocytes [47,48,51]. This evidence concerns the gene TNFRSF9 and neoplasm.